EUVIMEDEUVIMED entdecken
Crossref

Ligustilide Alleviates Renal Fibrosis Through Fblim1‐Dependent Inhibition of the TGF ‐β1/Smad3 Signaling Pathway

Quwu Mushuo, Jianchun Li, Shengkun Yang, Ling Luo, Yanqin Qiu, Li Wang, Qiong Zhang iD

Phytotherapy Research · 2026-05 · 40 (5) · 3063-3076

DOI: 10.1002/ptr.70305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 16.03.2026. Verfasst von Quwu Mushuo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Integrated Chinese and Western Medicine, Southwest Medical University, Luzhou, China. Hauptthemen laut MEDLINE: Smad3 Protein, Transforming Growth Factor beta1, Signal Transduction, 4-Butyrolactone. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Science and Technology Department of Sichuan Province, Joint Project of Luzhou Municipal People's Government and Southwest Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal fibrosis constitutes a central pathological hallmark of chronic kidney disease (CKD), with its progression largely mediated through the transforming growth factor‑β1 (TGF‑β1)/Smad3 signaling pathway. Ligustilide (LIG) has been reported to possess anti‑fibrotic activity; however, its protective effects and underlying molecular mechanisms in renal fibrosis remain incompletely understood. This study examined the effects of LIG and explored its underlying mechanisms in a unilateral ureteral obstruction (UUO) mouse model and TGF‑β1‐stimulated mouse renal tubular epithelial cell (TCMK1) cells. In vivo, LIG (20 and 40 mg·kg⁻ 1 ) significantly alleviated renal pathological injury in UUO mice, reduced tubular dilatation, and downregulated the expression of the renal injury marker KIM‑1 as well as fibrosis‑related proteins, including fibronectin, collagen I, and α‑SMA. In vitro, LIG dose‑dependently inhibited TGF‑β1‑induced fibrotic responses in TCMK1 cells. Target screening using drug affinity responsive target stability (DARTS)‑coupled liquid chromatography–mass spectrometry (LC/MS) identified Fblim1 as a putative target of LIG. Cellular thermal shift assay (CETSA) and DARTS assays further confirmed that LIG directly binds to Fblim1, enhancing its thermal stability and protease resistance. Both in vivo and in vitro, LIG treatment reduced the mRNA and protein levels of Fblim1 and phosphorylated Smad3 (p‑Smad3). Notably, LIG suppressed the nuclear accumulation of Fblim1 and p‑Smad3, thereby attenuating TGF‑β1/Smad3‑mediated profibrotic signaling. The results reveal that ligustilide exerts its anti‑renal fibrotic effects by targeting Fblim1 and regulating the TGF‑β1/Smad3 signaling pathway, particularly its nuclear translocation process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smad3 ProteinTransforming Growth Factor beta1Signal Transduction4-ButyrolactoneKidney DiseasesAnimalsFibrosisMiceUreteral ObstructionMaleCell LineKidneyMice, Inbred C57BLDisease Models, Animal

Stichwörter der Autor:innen

CKDFblim1Smad3ligustiliderenal fibrosis

Substanzen

Smad3 ProteinTransforming Growth Factor beta1ligustilide4-ButyrolactoneSmad3 protein, mouse

Autor:innen und Institutionen

  • Institute of Integrated Chinese and Western Medicine, Southwest Medical University, Luzhou, China.
  • Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.
  • Department of Nephrology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, China.

ORCID-Profile: Qiong Zhang

Förderung

  • National Natural Science Foundation of China
  • The Science and Technology Department of Sichuan Province
  • Joint Project of Luzhou Municipal People's Government and Southwest Medical University
  • The Funding Program of Southwest Medical University
  • Science and Technology Department of Sichuan Province

Zitieren

APA

Mushuo, Q., Li, J., Yang, S., Luo, L., Qiu, Y., Wang, L., & Zhang, Q. (2026). Ligustilide Alleviates Renal Fibrosis Through Fblim1‐Dependent Inhibition of the TGF ‐β1/Smad3 Signaling Pathway. Phytotherapy Research, 40(5), 3063-3076. https://doi.org/10.1002/ptr.70305

Vancouver

Mushuo Q, Li J, Yang S, Luo L, Qiu Y, Wang L, et al. Ligustilide Alleviates Renal Fibrosis Through Fblim1‐Dependent Inhibition of the TGF ‐β1/Smad3 Signaling Pathway. Phytotherapy Research. 2026;40(5):3063-3076. doi:10.1002/ptr.70305

BibTeX
@article{Mushuo2026,
  author = {Mushuo, Quwu and Li, Jianchun and Yang, Shengkun and Luo, Ling and Qiu, Yanqin and Wang, Li and Zhang, Qiong},
  title = {Ligustilide Alleviates Renal Fibrosis Through Fblim1‐Dependent Inhibition of the TGF ‐β1/Smad3 Signaling Pathway},
  journal = {Phytotherapy Research},
  year = {2026},
  volume = {40},
  number = {5},
  pages = {3063--3076},
  doi = {10.1002/ptr.70305}
}
Kostenlos starten →